Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies.

Details

Language :

English

ISSN :

0732183X

Volume :

27

Issue :

26

Database :

Supplemental Index

Journal :

Journal of Clinical Oncology

Publication Type :

Academic Journal

Accession number :

105427236

Full Text :

https://doi.org/10.1200/JCO.2008.20.8470